Evidence shows that clinicians are unfamiliar with the adverse event (AE) profiles and monitoring needs of immune checkpoint inhibitors (ICIs), creating a barrier to effective integration of these drugs. This enduring microburst learning activity aims to educate oncologists on how to optimize the use of immune checkpoint inhibitors (ICIs) in patients with unresectable, locally advanced (LA), recurrent, or metastatic cutaneous squamous cell carcinoma (cSCC). As a result of this educational activity, learners should be better able to: 1. Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic cSCC 2. Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic cSCC 3. Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic cSCC who are on immunotherapies. This activity is a Q&A based, audiovisual format combining 5 succinct session of 2-3-minute increments of education. Learners will have the opportunity to view a list of all sessions to allow easy access to those of greatest interest. Downloadable slides will be included and available for learners to download for use in clinical practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/JZC
- Start Date: 2024-11-06 06:00:00
- End Date: 2024-11-06 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Merck (Any division) - Amount: 153008.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all